{
  "question_stem": {
    "en": "A 45-year-old woman is hospitalized due to severe *Pneumocystis* pneumonia. The patient has a history of injection drug use and was diagnosed with HIV 10 years ago. She does not adhere to antiretroviral therapy and has developed resistance to multiple antiretroviral medications. Laboratory evaluation reveals severe immunosuppression with a high HIV viral load. After the patient is adequately treated for pneumonia, HIV genotypic analysis is performed. The viral isolates are found to have a mutation in the variable (V3) region of the *env* gene, which makes the virus capable of infecting T cells with a specific surface receptor, but infection of macrophages is inefficient.",
    "zh": "一名45岁女性因严重的*肺孢子虫*肺炎住院。患者有注射毒品的病史，10年前被诊断为HIV感染。她不遵守抗逆转录病毒治疗方案，并已对多种抗逆转录病毒药物产生耐药性。实验室评估显示严重的免疫抑制，伴有高HIV病毒载量。在患者接受充分的肺炎治疗后，进行HIV基因型分析。发现病毒分离株在*env*基因的可变(V3)区发生突变，这使得病毒能够感染具有特定表面受体的T细胞，但对巨噬细胞的感染效率低下。"
  },
  "question": {
    "en": "Which of the following antiretroviral medications is most likely to be ineffective in this patient?",
    "zh": "以下哪种抗逆转录病毒药物最有可能对该患者无效？"
  },
  "options": {
    "A": {
      "en": "Atazanavir",
      "zh": "阿扎那韦"
    },
    "B": {
      "en": "Efavirenz",
      "zh": "依非韦伦"
    },
    "C": {
      "en": "Enfuvirtide",
      "zh": "恩夫韦肽"
    },
    "D": {
      "en": "Maraviroc",
      "zh": "马拉维罗"
    },
    "E": {
      "en": "Raltegravir",
      "zh": "雷特格韦"
    },
    "F": {
      "en": "Tenofovir",
      "zh": "替诺福韦"
    }
  },
  "correct_answer": "D",
  "explanation": {
    "en": "The laboratory results in this case indicate an X4 virus (T lymphotropic with minimal macrophage invasion). Patients with X4 virus cannot be treated with HIV medications that target CCR5 (eg, **maraviroc**) because the X4 virus uses CXCR4, not CCR5, to enter cells.\n\n(Choice A) Protease inhibitors (eg, atazanavir, indinavir, darunavir) inhibit HIV protease from cleaving HIV polyproteins into the individual, functional proteins that compose the virus. This results in the formation of immature, noninfectious virions that are unable to infect T cells or macrophages.\n\n(Choices B and F) Non-nucleoside reverse transcriptase inhibitors (eg, efavirenz, nevirapine) allosterically bind reverse transcriptase, which alters its shape and prevents it from converting the HIV RNA genome into complementary DNA (cDNA). Nucleoside reverse transcriptase inhibitors (eg, tenofovir, emtricitabine) competitively bind reverse transcriptase and are integrated into growing cDNA strands, which results in chain termination. Both of these HIV medication classes truncate viral replication but do not affect viral attachment or fusion.\n\n(Choice C) Enfuvirtide is an HIV fusion inhibitor that binds to the HIV transmembrane surface protein glycoprotein 41 and prevents the virus from fusing with the host cell membrane. Fusion inhibitors would inhibit the ability of HIV to invade both lymphocytes and macrophages.\n\n(Choice E) Integrase inhibitors (eg, raltegravir, dolutegravir) prevent the HIV enzyme integrase from incorporating viral cDNA into the host chromosome, which prevents viral replication. They do not affect viral attachment or fusion.\n\nEducational objective:\nR5 strains (macrophage-tropic) of HIV attach to the host CD4 receptor and CCR5 chemokine coreceptor; CCR5 inhibitors such as maraviroc can be used in the treatment of R5 virus. X4 strains (T lymphotropic) of HIV bind to the CD4 receptor and CXCR4 chemokine receptor; X4 virus cannot be treated with CCR5 inhibitors.",
    "zh": "本例中的实验室结果表明存在X4病毒（T淋巴细胞趋向性，巨噬细胞侵袭最小）。X4病毒患者不能用靶向CCR5的HIV药物（例如，**马拉维罗**）治疗，因为X4病毒使用CXCR4（而不是CCR5）进入细胞。\n\n（选项A）蛋白酶抑制剂（例如，阿扎那韦、茚地那韦、达芦那韦）抑制HIV蛋白酶将HIV多蛋白切割成构成病毒的单个功能性蛋白。这导致形成不成熟的、无感染性的病毒颗粒，这些病毒颗粒无法感染T细胞或巨噬细胞。\n\n（选项B和F）非核苷类逆转录酶抑制剂（例如，依非韦伦、奈韦拉平）变构结合逆转录酶，改变其形状并阻止其将HIV RNA基因组转化为互补DNA（cDNA）。核苷类逆转录酶抑制剂（例如，替诺福韦、恩曲他滨）竞争性地结合逆转录酶并整合到生长的cDNA链中，导致链终止。这两种HIV药物类别都截断了病毒复制，但不会影响病毒的附着或融合。\n\n（选项C）恩夫韦肽是一种HIV融合抑制剂，它与HIV跨膜表面蛋白糖蛋白41结合，阻止病毒与宿主细胞膜融合。融合抑制剂会抑制HIV侵入淋巴细胞和巨噬细胞的能力。\n\n（选项E）整合酶抑制剂（例如，雷特格韦、多替拉韦）阻止HIV酶整合酶将病毒cDNA整合到宿主染色体中，从而阻止病毒复制。它们不影响病毒的附着或融合。\n\n教育目标：\nR5株（巨噬细胞趋向性）HIV附着于宿主CD4受体和CCR5趋化因子辅助受体；CCR5抑制剂如马拉维罗可用于治疗R5病毒。X4株（T淋巴细胞趋向性）HIV与CD4受体和CXCR4趋化因子受体结合；X4病毒不能用CCR5抑制剂治疗。"
  },
  "summary": {
    "en": "This question tests knowledge of HIV tropism and the mechanism of action of antiretroviral medications, specifically CCR5 inhibitors. It requires understanding how mutations in the *env* gene affect viral entry and drug susceptibility.\n\nTo solve this question, identify the viral tropism (X4 in this case) based on the mutation described. Then, recognize that CCR5 inhibitors like maraviroc are ineffective against X4 viruses because they target a different co-receptor (CCR5) than the one used by X4 viruses (CXCR4).",
    "zh": "本题测试对HIV趋向性和抗逆转录病毒药物（特别是CCR5抑制剂）作用机制的了解。它需要理解*env*基因中的突变如何影响病毒进入和药物敏感性。\n\n要解决这个问题，根据所描述的突变识别病毒趋向性（在本例中为X4）。然后，认识到CCR5抑制剂（如马拉维罗）对X4病毒无效，因为它们靶向的辅助受体（CCR5）与X4病毒使用的辅助受体（CXCR4）不同。"
  },
  "tags": "HIV; Antiretroviral therapy; Maraviroc; CCR5 inhibitors; Viral tropism; X4 virus; CXCR4; env gene; Infectious diseases; Pharmacology",
  "category": "Micro",
  "question_id": "15107",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Micro 23\\15107",
  "extracted_at": "2025-11-05T14:57:01.929546",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T18:08:11.181835",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}